Tags

Type your tag names separated by a space and hit enter

One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial.
Acta Derm Venereol. 2010 Mar; 90(2):170-4.AD

Abstract

A one-year, randomized, double-blind study was conducted in 80 patients with atopic dermatitis treated with tacrolimus ointment or a corticosteroid regimen (hydrocortisone acetate 1% ointment for head and neck, hydrocortisone butyrate 0.1% ointment for trunk and limbs) to compare efficacy and safety, and effects on Th2-reactivity. The study was completed by 36/40 patients in the tacrolimus group, and 31/40 patients in the corticosteroid group. In both groups affected body surface area, eczema area and severity index, and transepidermal water loss decreased at months 6 and 12. Tacrolimus was superior for all efficacy scores at month 6, and in the head and neck area at month 12. Recall antigen reactivity increased at month 12 in both groups. Adverse events were reported by 40/40 patients in the tacrolimus, and by 34/40 patients in the corticosteroid group. Long-term treatment with topical tacrolimus or a corticosteroid regimen improves atopic dermatitis and recall antigen reactivity, suggesting an improvement in the Th1/Th2-balance.

Authors+Show Affiliations

Skin and Allergy Hospital, Department of Dermatology, Helsinki University Central Hospital, Finland. johanna.mandelin@hus.fiNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20169301

Citation

Mandelin, Johanna, et al. "One-year Treatment With 0.1% Tacrolimus Ointment Versus a Corticosteroid Regimen in Adults With Moderate to Severe Atopic Dermatitis: a Randomized, Double-blind, Comparative Trial." Acta Dermato-venereologica, vol. 90, no. 2, 2010, pp. 170-4.
Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. Acta Derm Venereol. 2010;90(2):170-4.
Mandelin, J., Remitz, A., Virtanen, H., & Reitamo, S. (2010). One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. Acta Dermato-venereologica, 90(2), 170-4. https://doi.org/10.2340/00015555-0803
Mandelin J, et al. One-year Treatment With 0.1% Tacrolimus Ointment Versus a Corticosteroid Regimen in Adults With Moderate to Severe Atopic Dermatitis: a Randomized, Double-blind, Comparative Trial. Acta Derm Venereol. 2010;90(2):170-4. PubMed PMID: 20169301.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized, double-blind, comparative trial. AU - Mandelin,Johanna, AU - Remitz,Anita, AU - Virtanen,Hannele, AU - Reitamo,Sakari, PY - 2010/2/20/entrez PY - 2010/2/20/pubmed PY - 2010/5/7/medline SP - 170 EP - 4 JF - Acta dermato-venereologica JO - Acta Derm Venereol VL - 90 IS - 2 N2 - A one-year, randomized, double-blind study was conducted in 80 patients with atopic dermatitis treated with tacrolimus ointment or a corticosteroid regimen (hydrocortisone acetate 1% ointment for head and neck, hydrocortisone butyrate 0.1% ointment for trunk and limbs) to compare efficacy and safety, and effects on Th2-reactivity. The study was completed by 36/40 patients in the tacrolimus group, and 31/40 patients in the corticosteroid group. In both groups affected body surface area, eczema area and severity index, and transepidermal water loss decreased at months 6 and 12. Tacrolimus was superior for all efficacy scores at month 6, and in the head and neck area at month 12. Recall antigen reactivity increased at month 12 in both groups. Adverse events were reported by 40/40 patients in the tacrolimus, and by 34/40 patients in the corticosteroid group. Long-term treatment with topical tacrolimus or a corticosteroid regimen improves atopic dermatitis and recall antigen reactivity, suggesting an improvement in the Th1/Th2-balance. SN - 1651-2057 UR - https://www.unboundmedicine.com/medline/citation/20169301/One_year_treatment_with_0_1_tacrolimus_ointment_versus_a_corticosteroid_regimen_in_adults_with_moderate_to_severe_atopic_dermatitis:_A_randomized_double_blind_comparative_trial_ L2 - https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-0803 DB - PRIME DP - Unbound Medicine ER -